CERo Therapeutics Holdings, Inc. · OTC:CERO
CERo Therapeutics — Investor Presentation (September 2025)
22 slides from CERo Therapeutics's investor presentation, Sep 22, 2025
Slide 1: Investor Presentation September 2025
INVESTOR PRESENTATION September 2025 NASDAQ: CERO
Slide 2: Disclaimer
NASDAQ: CERO This presentation (this “Presentation”) is provided for informational purposes only and for no other purpose and has been prepared to assist interested parties in making their own evaluation with respect to a potential investment in CERo Therapeutics Holdings, Inc . (“CERo”) . The infor
Slide 3: A Simple Idea Became a Novel, Powerful Therapeutic
A Simple Idea Became a Novel, Powerful Therapeutic Engineering Engulfment into T Cells 3
Slide 4: Investment Highlights
NASDAQ: CERO Investment Highlights • Novel Mechanism of Action (MOA) and Strong Scientific Rationale - Novel Chimeric Engulfment Receptor T cells (CER - T) platform redirects patient - cells to eliminate tumors by building in engulfment pathways that employ phagocytic mechanisms - Proprietary, multi
Slide 5: Designed with the Best Parts of the Immune System – T-Cells and Macrophages
NASDAQ: CERO Designed with the Best Parts of the Immune System – T - Cells and Macrophages • Home to target cells • Rapidly multiply at site of target cells (tumor) • Punch holes in target cells • Signal rest of immune system • Form molecular memory , and persist • Eat (Phagocytosis) targeted tumor
Slide 6: What is a CER-T Cell?
NASDAQ: CERO What is a CER - T Cell? himeric ngulfment eceptor C E R Uses TIM - 4 Phagocytic Receptor to Engage Tumor Targets via the Cell of Damaged Receptor TIM - 4 Ligand Tumor Cell TIM 4 Ligand T umor Cell CER - T Cell Multifunctional Construct Transmembrane Extracellular Domain Tumor binding an
Slide 7: CER-T Development Pipeline
NASDAQ: CERO 7 CER - T Development Pipeline Pivotal Phase 2 / BLA Enabling Phase 2 Phase 1 Preclinical Development Regulatory Status Indication Orphan Drug and Fast Track Status AML Solid tumors – Ovarian Solid tumors – NSCLC
Slide 8: In Vivo Evidence of Anti-Tumor Killing
NASDAQ: CERO 0 10 20 30 40 50 0 500 1000 1500 2000 Days post T cell infusion T u m o r V o l u m e ( m m 3 ± S E M ) No T cells Untransduced T cells CER T cells In Vivo Evidence of Anti - Tumor Killing A single infusion of CER - T cells specifically kills non - small cell lung cancer (NSCLC) cells E
Slide 9: CER-T Cells Eliminate Mantle Cell Lymphoma Xenografts In Vivo
NASDAQ: CERO CER - T Cells Eliminate Mantle Cell Lymphoma Xenografts In Vivo A Single Infusion of CER - 1236 T Cells Eliminated TP53 mutant Mantle Cell Lymphoma tumors Single infusion of 2.5e^6 CER - 1236 T cells 0 20 40 10 4 10 5 10 6 10 7 10 8 10 9 10 10 Day post T cell infusion B L I ( t o t a l
Slide 10: Elimination of p53 Mutant AML Cell Lines in Mice
NASDAQ: CERO Elimination of p53 Mutant AML Cell Lines in Mice Dose Level I 5e^6 CER - 1236 T cells per mouse D + 50: 3 - log reduction in tumor No Treatment Untransduced T Cells CER - 1236 T Cells Day - 14 Kasumi - 1 Tumor inoculation 2e^6 cells/ mouse Day 0 T cell infusion Weekly BLI Measurements W
Slide 11: CER-1236 T Cells have not Shown Toxicity in Animal Tumor Models
NASDAQ: CERO CER - 1236 T Cells have not Shown Toxicity in Animal Tumor Models Single infusion of 7.5e^6 CER - 1236 T cells NO anemia, thrombocytopenia, neutropenia, or coagulation abnormalities NO weight loss, morbidity, unexpected mortality NO histological abnormalities across organs A Single Infu
Slide 12: Robust Off-Target Safety Data
NASDAQ: CERO Robust Off - Target Safety Data No CER - 1236 T cell activation or cytotoxic T cell function observed against primary human cells representing central nervous system, heart, lungs, liver, GI tract, kidneys, spleen, or gonads. NO Off - target responses to primary human cells No T cell ac
Slide 13: Significant Unmet Needs in AML
NASDAQ: CERO 13 Significant Unmet Needs in AML • Relapsed/Refractory Subset ⎼ Allogeneic Hematopoietic Cell Transplant (HCT) is only curative option… ⎼ …but HCT is not an option if patient cannot achieve a Complete Response in prior therapy ⎼ Early Trial Endpoint: Complete Response (CR) • P53 – Subs
Slide 14: Clinical Design – AML
NASDAQ: CERO 14 Clinical Design – AML ~21 days
Slide 15: Clinical Design – Solid Tumor Study
NASDAQ: CERO 15 Clinical Design – Solid Tumor Study
Slide 16: Early Results and Anticipated Timeline
NASDAQ: CERO 16 Early Results and Anticipated Timeline • First patient dosed on May 20, 2025 ⎼ No dose - limiting toxicity at 28 days ⎼ Encouraging PK response • Second patient dosed end of July ⎼ Encouraging PK and initial immune response ⎼ Patient received second dose early September • Third patie
Slide 17: CERo Anticipated Timeline for 2H 2025 - Q1 2026
NASDAQ: CERO 17 CERo Anticipated Timeline for 2H 2025 - Q1 2026 Q3 (2025) Q4 (2025) • Additional 2 AML patients dosed • Investor conferences • Second dose cohort for AML • Investor conferences • Data presented at Medical Conference(s) Q1 (2026) • Data from second cohort of AML patients • Data from f
Slide 18: Patent Portfolio Overview
NASDAQ: CERO 18 Patent Portfolio Overview • 9 Total Patent Families • 4 issued US patents – 3 of which relate to CER - 1236, including a patent that covers genus of PtdSer targeting CERs with TLR signaling domain • Key patents with protection out to 2037 (EP), 2038 (CN and JP), 2042 (US) • 20 issuan
Slide 19: • CEO, Launch One Acquisition Corp • Former CEO, Phoenix Biotech Acquisition Corp •
NASDAQ: CERO • CEO, Launch One Acquisition Corp • Former CEO, Phoenix Biotech Acquisition Corp • Former CEO, Locust Walk Acquisition Corp • Former Senior Managing Director, Locust Walk • Former General Partner, Interwest Partners • Genentech, LEK Consulting • Adjunct Professor, University of San Fra
Slide 20: Board of Directors
NASDAQ: CERO 20 Board of Directors • CEO, Launch One Acquisition Corp. • Former CEO, Phoenix Biotech Acquisition Corp • Former CEO, Locust Walk Acquisition Corp • Former Senior Managing Director, Locust Walk • Former General Partner, Interwest Partners • Genentech, LEK Consulting Chris Ehrlich Chief
Slide 21: The Next Era in Cancer Cell Therapy
NASDAQ: CERO The Next Era in Cancer Cell Therapy (NASDAQ: CERO) NOVEL APPROACH Powerful, multi - functional tumor clearing NEAR TERM VALUE Human data in 2025 - 26 PROVEN SUCCESS Experienced team, top investors, capital efficient LARGE OPPORTUNITY Target prevalent across many tumor types Designed and
Slide 22: Contact Details
Contact Details Investor & Media Relations: CORE IR Matt Blazei mattb@coreir.com Media Inquiries: CORE IR Jules Abraham julesa@coreir.com 22
CERo Therapeutics Holdings — Investor Presentation (September 2025) on 6ix